STOCK TITAN
  1. Home
  2. Sec-filings
  3. EPRX
  4. [6-K] EUPRAXIA PHARMACEUTICALS INC. Current Report (Foreign Issuer)

Eupraxia Pharmaceuticals (EPRX) reshapes leadership and expands Vancouver-Seattle hubs

Filing Impact
(Neutral)
Filing Sentiment
(Neutral)
Form Type
6-K

Rhea-AI Filing Summary

Eupraxia Pharmaceuticals Inc. announced significant updates to its executive leadership and operating structure as it prepares for its next stage of clinical and commercial development. Dr. Jeff Millard joined as Executive Vice President, Technical Operations, effective July 13, 2026, and Dr. Alex Therien will lead Research & Development in his role as Executive Vice President, Research & Development.

The company has transitioned its operations from Victoria to Vancouver and Seattle, evolving into a cross-border two-hub organization. Key clinical, manufacturing and commercial executive roles, including the CEO, will be based in Seattle. As part of this transition, Amanda Malone stepped down as Chief Scientific and Operating Officer effective July 10, 2026.

Positive

  • None.

Negative

  • None.
Appointment date of EVP Technical Operations July 13, 2026 Dr. Jeff Millard joined as Executive Vice President, Technical Operations effective July 13, 2026.
Effective date for EVP Research & Development leadership July 13, 2026 On July 13, 2026, Dr. Alex Therien took the helm of Research & Development as Executive Vice President, Research & Development.
Departure date of Chief Scientific and Operating Officer July 10, 2026 Amanda Malone stepped down from her role as Chief Scientific and Operating Officer effective July 10, 2026.
News release date announcing material change July 13, 2026 A news release announcing the material change was issued on July 13, 2026 through Globe Newswire.
Material Change Report regulatory
"Exhibit 99.1 FORM 51-102F3 MATERIAL CHANGE REPORT Eupraxia Pharmaceuticals Inc."
A material change report is a public notice that a company must file and share whenever new information or an event is significant enough to likely influence an investor’s decision. Think of it like an urgent update board that tells shareholders about big shifts—such as major deals, leadership changes, sudden losses, or legal issues—so investors can reassess risk and value with the same facts everyone else has.
Executive Vice President, Technical Operations other
"Dr. Jeff Millard has joined Eupraxia as Executive Vice President, Technical Operations"
Executive Vice President, Research & Development other
"will take the helm of Research & Development in his role as Executive Vice President, Research & Development"
cross-border two-hub organization other
"As Eupraxia evolves into a cross-border two-hub organization, Eupraxia has completed the transition"
clinical and commercial development medical
"as the Company continues to prepare for its next stage of clinical and commercial development"

AI-generated analysis. How Rhea-AI works. Not financial advice.

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google
Add on Google
Form 6-K: How Foreign Companies Report to the SEC →

FAQ

What leadership changes did Eupraxia Pharmaceuticals (EPRX) announce in July 2026?
Eupraxia Pharmaceuticals announced executive leadership updates, including appointing Dr. Jeff Millard as EVP Technical Operations, assigning Dr. Alex Therien to lead R&D as EVP Research & Development, and the departure of Chief Scientific and Operating Officer Amanda Malone effective July 10, 2026.

How is Eupraxia Pharmaceuticals (EPRX) changing its operating structure?
Eupraxia is evolving into a cross-border two-hub organization, completing the transition of operations from Victoria to Vancouver and Seattle. Key clinical, manufacturing and commercial executive leadership roles, including the CEO, will now be based in the company’s Seattle offices.

When did Dr. Jeff Millard join Eupraxia Pharmaceuticals (EPRX) and in what role?
Dr. Jeff Millard joined Eupraxia on July 13, 2026 as Executive Vice President, Technical Operations. His role supports the company’s preparations for its next stage of clinical and commercial development, strengthening technical operations across its new Vancouver and Seattle hubs.

What is Dr. Alex Therien’s role at Eupraxia Pharmaceuticals (EPRX)?
Dr. Alex Therien serves as Executive Vice President, Research & Development and will take the helm of R&D. He originally joined Eupraxia in November 2025 and now leads research and development activities as the company scales clinical and commercial operations.

Which executive departed Eupraxia Pharmaceuticals (EPRX) and when?
Amanda Malone stepped down as Chief Scientific and Operating Officer, effective July 10, 2026. She was based in Victoria, and her departure aligns with Eupraxia’s transition of operations to Vancouver and Seattle; the company expressed gratitude for her contributions to early-stage development.

How can investors contact Eupraxia Pharmaceuticals (EPRX) about the July 2026 changes?
Investors can contact Chief Executive Officer James A. Helliwell at telephone number 250-590-3968. The company’s address is 2198 Yukon Street, Vancouver, British Columbia, V5Y 3P1, which serves as its principal location for corporate correspondence and inquiries.
 

UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

Form 6-K

REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934

For the month of July 2026

Commission File Number: 001-41923

EUPRAXIA PHARMACEUTICALS INC.
(Exact name of Registrant as specified in its charter)

N/A
(Translation of Registrant’s name)

2198 Yukon Street
Vancouver, British Columbia, Canada V5Y 3P1
Telephone: (250) 590-3968 
(Address and telephone number of registrant’s principal executive office)

Indicate by check mark whether the registrant files or will file annual reports under cover of Form 20-F or Form 40-F.
Form 20-F [   ]      Form 40-F [ X ]

 

 

DOCUMENTS INCLUDED AS PART OF THIS REPORT

Exhibit  
  
99.1 Material Change Report

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized.

  EUPRAXIA PHARMACEUTICALS INC.
   
  
Date: July 15, 2026 By: /s/ Alex Rothwell                     
  Name: Alex Rothwell
  Title: Chief Financial Officer
  

Exhibit 99.1

 

FORM 51-102F3

MATERIAL CHANGE REPORT

 

Item 1:Name and Address of Company

 

Eupraxia Pharmaceuticals Inc. (the “Company”)

2198 Yukon Street,

Vancouver, British Columbia,

Canada, V5Y 3P1

 

Item 2:Date of Material Change

 

July 13, 2026

 

Item 3:News Release

 

A news release announcing the material change was issued on July 13, 2026 through Globe Newswire and a copy was subsequently filed on SEDAR+.

 

Item 4:Summary of Material Change

 

On July 13, 2026, the Company announced updates to its executive leadership and operating structure as the Company continues to prepare for its next stage of clinical and commercial development.

 

Item 5.1:Full Description of Material Change

 

On July 13, 2026, the Company announced updates to its executive leadership and operating structure as the Company continues to prepare for its next stage of clinical and commercial development.

 

Dr. Jeff Millard has joined Eupraxia as Executive Vice President, Technical Operations, effective July 13, 2026.

 

As part of these changes, Dr. Alex Therien, who joined Eupraxia in November 2025, will take the helm of Research & Development in his role as Executive Vice President, Research & Development.

 

As Eupraxia evolves into a cross-border two-hub organization, Eupraxia has completed the transition of its operations from Victoria to Vancouver and Seattle, reflecting the Company’s focus on supporting its growing clinical operations. Key clinical, manufacturing and commercial executive leadership positions, including the CEO, will be based in the Seattle offices.

 

As part of this transition, Amanda Malone, based in Victoria, has stepped down from her role as Chief Scientific and Operating Officer, effective July 10, 2026. Eupraxia is grateful for her years of expertise in research and early-stage development.

 

Item 5.2:Disclosure of Restructuring Transactions

 

Not applicable.

 

 

 

Item 6:Reliance on subsection 7.1(2) of National Instrument 51-102

 

Not applicable.

 

Item 7:Omitted Information

 

Not applicable.

 

Item 8:Executive Officer

 

For further information, please contact James A. Helliwell, Chief Executive Officer of the Company at 250-590-3968.

 

Item 9:Date of Report

 

July 15, 2026

 

 

Source: View Original Filing on SEC EDGAR

Filing Exhibits & Attachments

1 document

Press Releases